A History of Diagnostic Contribution to Antimicrobial Stewardship

1989 | **Clearview® Strep A**: a 5 minute rapid test to diagnose Strep A pharyngitis and prevent the use of unnecessary antibiotics for patients with viral pharyngitis.

1994 | The world's first **Legionella ELISA test** for the presumptive diagnosis, treatment and management of Legionnaires' disease.

1998 | The world's first rapid *L. pneumophila* urinary antigen test aiding the rapid diagnosis and appropriate therapy for Legionnaires' disease within 15 minutes.

1999 | The unique urinary antigen test for **Streptococcus pneumoniae**: aiding in the diagnosis of pneumococcal pneumonia and appropriate narrow spectrum antibiotics.

2000 | The quantitative **NycoCard™ CRP Single Test** and **NycoCard™ Reader** are launched.

2002 | **Alere BinaxNOW® Influenza A&B tests**: allowing avoidance of unnecessary antibiotics and prudent use of antivirals within 15 minutes.

2003 | **Alere BinaxNOW® RSV**: a 15 minute test assisting the physician to withhold unnecessary antibiotics.

2005 | The fully automated **Alere Afinion™ CRP** point-of-care immunoassay is launched on the **Alere Afinion™ Analyzer**. This 4 minute test makes it even easier to discriminate serious illness such as pneumonia from often self-limiting illness like acute bronchitis and other RTI in a primary care setting.

2009 | **C. DIFF QUIK CHEK COMPLETE** (TechLab®, Inc.): a unique rapid test for the detection of Clostridium difficile. This Healthcare Associated Infection (HAI) is often a consequence of poor Antimicrobial Stewardship (AMS).

2010 | **The Alere™ PBP2a Culture Colony Test**: Aids in identifying MRSA from bacterial isolates identified as Staphylococcus aureus in 6 minutes. This can be up to 24 hours sooner than traditional methods.

2012 | **Shiga Toxin QUIK CHEK** (TechLab®, Inc.): a unique test for the detection of *Vero*-toxigenic (VTEC) *E. coli* directly from a stool sample. Antibiotic treatment for VTEC can increase the risk of secondary complications.

2013 | **Alere™ | Influenza A & B**, the first CLIA-waived point of care rapid molecular test aiding the diagnosis of influenza, enabling better treatment management and AMS.

2015 | **Alere™ | Strep A**: The speed and accuracy of the **Alere™ | Strep A** test empowers healthcare professionals to initiate the right treatment in an actionable time-frame.

2015 | **The Alere™ PBP2a SA Culture Colony Test**: Aids in identifying MRSA from bacterial isolates identified as Staphylococcus aureus in 6 minutes. This can be up to 24 hours sooner than traditional methods. Product has been optimized with improvements to procedure and room temp storage.

2015 | **Alere™ | RSV**: The first molecular test that can be used at the point-of-care to detect RSV in 13 minutes or less.